Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Indian Journal of Medical and Paediatric Oncology
Search Article 
  
Advanced search 
 
Year : 2003  |  Volume : 24  |  Issue : 3  |  Page : 5-8

Ifosfamide based intensive mcp-842 protocol in diffuse intermediate and High-grade non-Hodgkin's lymphoma


Division of Medical Oncology, Cancer Institute (WIA), Chennai, India

Correspondence Address:
TG Sagar
Division of Medical Oncology, Cancer Institute (WIA), Chennai, India

Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

Background: CHOP (Cyclophosphamide, Vincristine, adriamycin and prednisolone) is the standard chemotherapy for intermediate and high grade none Hodgkin's lymphoma (NHL). We evaluated a new third generation combination chemotherapy protocol 'MCP 842' for the treatment of patients with advanced NHL. Patients and methods: 110 patients with aggressive diffuse NHL of intermediate and high grade (Working formulation) were treated with 'MCP 842' between December, 1985 and December, 1993. The protocol was designed in collaboration with the paediatric branch of National Cancer Institute, Bethesda, Maryland, USA. This protocol contains 7 drug comprising myelosuppressive and non or less myelosuppressive drugs administered alternately. Results: Patients median age was 35 years, male to female ratio being 2.79 :1 Ann Arbor staging revealed-stage I-10 percent, II-31 percent, III-39 percent and stage IV in 20 percent of patients. 36.4 percent of patients had B symptoms. 52 percent of patients had high grade and 48 percent had intermediate grade histology as per working formulation. Following chemotherapy 66.4 percent of patients achieved CR. Response rate was significantly higher in patients with early stage (stage I-II vs III-IV; 80 percent vs 57 percent, p.08), absence of `B' symptoms (78 percent vs 45 percent p.001) and in those with absence of bulky abdominal lymph nodes (p.001). Kaplan Meier probability of event-free and disease-free survival at 5 years was 48.3 percent and 69.5 percent, respectively. Marrow toxicity was the predominant toxicity and there were three infection related deaths. Concussions: In our hands, results of this new third generation protocol were not superior to those reported with standard CHOP.


[PDF Not available]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1629    
    Printed108    
    Emailed1    
    PDF Downloaded0    
    Comments [Add]    

Recommend this journal